
Sacubitril/valsartan improves cardiac function in Chinese patients with heart failure: a real‐world study
Author(s) -
Chen Wenwen,
Liu Yanlin,
Li Yuanmin,
Dang Heqin
Publication year - 2021
Publication title -
esc heart failure
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.787
H-Index - 25
ISSN - 2055-5822
DOI - 10.1002/ehf2.13491
Subject(s) - sacubitril , medicine , valsartan , interquartile range , ejection fraction , sacubitril, valsartan , heart failure , cardiology , cardiac function curve , diastole , blood pressure
Aims Sacubitril/valsartan significantly reduced heart failure (HF) hospitalization and cardiovascular mortality in a randomized controlled trial. However, little is known about real‐world efficacy and safety of sacubitril/valsartan in Chinese patients with HF with reduced ejection fraction (HFrEF). We aimed to evaluate whether sacubitril/valsartan could improve cardiac function in Chinese patients with HFrEF in a tertiary hospital in China. Methods and results Patients with HFrEF receiving sacubitril/valsartan in our hospital between January 2018 and January 2020 were recruited in the present study. We retrospectively collected and analysed all clinical parameters at baseline and during follow‐up. A total of 100 consecutive patients (73% male) with HFrEF were recruited in the present study. During a median follow‐up period of 365 days [interquartile range (IQR), 346–378], a pronounced improvement of cardiac function was achieved. New York Heart Association classification was significantly improved ( P < 0.001), and median N‐terminal pro‐B‐type natriuretic peptides level significantly decreased from 3003 pg/mL (IQR, 1513–5404) to 2039 pg/mL (IQR, 921–3955) ( P = 0.010). Mean left ventricular ejection fraction increased from 31 ± 6% to 38 ± 10% ( P < 0.001) and median left ventricular end‐diastolic diameter reduced from 63 mm (IQR, 59–67) to 60 mm (IQR, 55–68) ( P = 0.001). Mean pulmonary arterial systolic pressure decreased significantly from 49 ± 13 mmHg to 44 ± 12 mmHg ( P < 0.001) and median right ventricular end‐diastolic diameter reduced from 23 mm (IQR, 21–26) to 22 mm (IQR, 20–25) ( P = 0.030). After treatment with sacubitril/valsartan, mean estimated glomerular filtration rate significantly decreased (from 88.8 ± 22.4 mL/min to 71.8 ± 27.3 mL/min, P < 0.001). Median serum creatinine and median blood urea nitrogen levels significantly increased [from 0.9 mg/dL (IQR, 0.8–1.0) to 1.1 mg/dL (IQR, 0.9–1.3), P < 0.001, and from 6.8 mmol/L (IQR, 5.5–8.9) to 8.0 mmol/L (IQR, 6.6–10.3), P = 0.002, respectively]. The proportion of patients with chronic kidney disease Stage 3/4 increased significantly from 8% to 39% ( P < 0.001). Conclusions In Chinese patients with HFrEF, sacubitril/valsartan treatment was associated with a pronounced improvement of cardiac function, but might be prone to a decrease in blood pressure and deterioration in renal function.